HAMMAD BOKHARI: Open Payments
NPI 1104832161 · JEFFERSONVILLE, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,227 in 64 payments from 21 companies in 2025. Trend: 2023 $649 · 2024 $1,060 · 2025 $1,227
Food & beverage: $1,227
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $257 |
| AstraZeneca Pharmaceuticals LP | 7 | $152 |
| Otsuka America Pharmaceutical, Inc. | 5 | $113 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $107 |
| Lilly USA, LLC | 4 | $86 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $59 |
| Vanda Pharmaceuticals Inc. | 2 | $56 |
| Axsome Therapeutics, Inc. | 2 | $50 |
| Verona Pharma, Inc. | 3 | $47 |
| Novo Nordisk Inc | 3 | $46 |
Products named: VRAYLAR, REXULTI, Kerendia, BREZTRI, MOUNJARO, CAPLYTA, HETLIOZ, AIRSUPRA.
Industry payments across IN — which companies pay providers there.
